Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Vascular Biology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for EPN1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | EPN1 Recombinant Protein (ENTH Domain / Full Length) High purity (>95%), Endotoxin controlled. Sequence Verified. |
View EPN1 Products |
| Gene Delivery | EPN1 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and endocytosis assays. |
View EPN1 Products |
| Benchmark Ab | Anti-EPN1 Recombinant Antibody Recombinant positive control for Western Blot, IHC, and IP. |
View EPN1 Products |
| Validator | EPN1 siRNA Set Target-specific knockdown verification in functional assays. |
View EPN1 Products |
| Related Target A | NOTCH1 EPN1 regulates Notch ligand endocytosis; critical for tumor angiogenesis pathways. |
View NOTCH1 Products |
| Related Target B | VEGFR2 EPN1 selectively regulates VEGFR2 internalization and degradation in endothelial cells. |
View VEGFR2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Targeting intracellular protein-protein interactions (ENTH-PIP2/Ubiquitin) | High-purity recombinant ENTH domain proteins (>95% by SDS-PAGE) for robust biophysical binding assays. |
| Assessing functional endocytosis inhibition in vitro | Lentiviral vectors for stable EPN1 overexpression to establish high-throughput endocytosis screening cell lines. |
| Lack of reliable positive controls | Sequence-verified recombinant benchmark antibodies with high specificity to native EPN1 epitopes. |
| Off-target effects in RNAi assays | Sequence-optimized EPN1 siRNA sets with validated knockdown efficiency controls. |
Live EPN1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of EPN1 (Epsin-1) is emerging as a novel frontier in oncology, particularly in disrupting tumor angiogenesis and progression. EPN1 acts as a key endocytic adaptor protein that regulates the internalization of critical cell surface receptors, including Notch ligands and VEGFR2. Accumulating evidence indicates that EPN1 is upregulated in several aggressive cancers, including glioma, breast, and prostate cancers, where it drives pathological neovascularization.
While traditional anti-angiogenic therapies targeting VEGF ligands face resistance, modulating the endocytic machinery via EPN1 inhibition offers a highly selective alternative. Current drug discovery efforts are shifting from systemic pathway blockades to targeted small molecules, peptide mimetics, and RNA therapeutics designed to disrupt the Epsin N-terminal homology (ENTH) domain interaction with PIP2 or ubiquitin-binding motifs. The next wave of R&D is focused on combining EPN1 inhibition with immune checkpoint blockades to overcome the immunosuppressive tumor microenvironment.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule / Peptide | Academic Institutes, Biotech Startups | Solid Tumors, Glioma | Protein-Protein Interaction (PPI) assays requiring highly stable, monomeric ENTH domain proteins. |
| RNA Therapeutics (siRNA/shRNA) | RNAi-focused Biopharma | Advanced Solid Tumors | In vitro knockdown verification using sequence-validated siRNA pools and control cell lines. |
| Combination Therapies (mAbs) | Global Oncology Pharma | Angiogenic-rich Malignancies | Co-culture assays tracking VEGFR2/Notch internalization via stable EPN1-expressing cell models. |